Psyomics, a leading health technology company pioneering digital mental health solutions, is proud to announce that its CEO, Dr Melinda Rees, has been awarded a prestigious NHS Innovation Accelerator (NIA) Fellowship.
Psyomics is one of only two mental health products supported by the programme this year, marking a significant step forward in its mission to transform mental health care through its clinically informed digital innovation.
The NHS Innovation Accelerator is a highly selective programme that supports high-impact, evidence-based innovations to scale within the NHS. Backed by NHS England, the programme provides unparalleled access to NHS expertise, mentorship, and networks, enabling innovators to navigate the complexities of healthcare adoption and implementation.
Psyomics’ platform has been designed to streamline the start of the mental health journey, supporting providers’ efficiency, harmonising process by utilising technology to capture the service users’ voice from the beginning and reducing the need for them to repeat their stories at different points on the pathway to help.
“Our acceptance into the NIA is a game-changer,” said Dr Melinda Rees, CEO of Psyomics. “This partnership will accelerate our efforts to embed our digital mental health solutions into NHS services, making high-quality mental health support more accessible to those who need it most.”
Through the NIA, Psyomics will work closely with NHS leaders, clinicians, and policymakers to demonstrate real-world impact, and drive adoption across NHS provider services. The collaboration aligns with the government’s shift from analogue to digital in an area that is overdue support despite rapidly growing demand.
“Our goal is to bridge the gap between technology and healthcare, ensuring that every patient can benefit from the latest advancements in mental health services,” added Stuart John Chuan, Clinical Director at Psyomics. “By working alongside the NHS Innovation Accelerator, we are one step closer to making this vision a reality.”
In addition, Psyomics has also been selected to be part of the ABHI US and Middle East Accelerators, positioning the company to expand its market presence across key international healthcare systems alongside its participation in the NHS Innovation Accelerator.
Psyomics invites NHS professionals, partners, and stakeholders to engage with them as they embark on this journey to transform mental health services at scale.
Please visit https://www.psyomics.com/ to find out more.
